Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 21 of 21 publications.

Brufsky A, Kwan ML, Sandin R, Stergiopoulos S, Karanth S, Cha-Silva AS, Makari D, Goyal RK. Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2− and HER2+ metastatic breast cancer. Breast Cancer Res Treat. 2024 Nov;208(2):223-35. doi: 10.1007/s10549-024-07469-6

Goyal RK, Zhang J, Davis KL, Sluga-O'Callaghan M, Kaufman PA. Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior phosphoinositide 3-kinase inhibitor treatment for metastatic breast cancer. Breast Cancer Res Treat. 2024 May;205(1):201-10. doi: 10.1007/s10549-023-07080-1

Phillips T, Lugtenburg P, Kalsekar A, Mutebi A, Wang A, Blaedel J, Kosa K, Martin S, Sacchi M, Kilavuz N, Thieblemont C. Improvements in patient-reported outcomes in relapsed or refractory large b-cell lymphoma patients treated with epcoritamab. Clin Lymphoma Myeloma Leuk. 2023 Nov 27;24(3):e78-e87.e. doi: 10.1016/j.clml.2023.11.005

Goyal RK, Holmes HM, Chen H, Abughosh S, Candrilli SD, Johnson ML. Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2- metastatic breast cancer in the United States. Breast Cancer Res Treat. 2023 Feb;198(1):159-66. doi: 10.1007/s10549-022-06845-4

Cohen AD, Hari P, Htut M, Berdeja JG, Usmani SZ, Madduri D, Olyslager Y, Goldberg JD, Schecter JM, Jackson CC, Gries KS, Fastenau JM, Valluri S, Deraedt W, Akram M, Crawford R, Morrison R, Doward L, Morgan K, Seldam ST, Jakubowiak A, Jagannath S. Patient perceptions regarding ciltacabtagene autoleucel treatment: qualitative evidence from interviews with patients with relapsed/refractory multiple Myeloma in the CARTITUDE-1 study. Clin Lymphoma Myeloma Leuk. 2022 Nov 7;16:54. doi: /10.1016/j.clml.2022.10.001

Perez EA, Dang C, Lee C, Singh J, Wang K, Layton JB, Gilsenan A, Hackshaw MD, Cortes J. Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review. Breast Cancer Res Treat. 2022 Jul;194(1):1-11. doi: 10.1007/s10549-021-06469-0

Spira A, Zhou X, Chen L, Gnanasakthy A, Wang L, Ungar D, Curiel R, Liao L, Radford J, Kahl B. Health-related quality of life, symptoms, and tolerability of Loncastuximab Tesirine in patients with relapsed or refractory diffuse large b-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2022 Mar;22(3):158-68. doi: 10.1016/j.clml.2021.09.001

Joyner K, Galinsky J, Clavreul S. The impact of COVID-19 on the treatment regimens of myeloma and AL amyloidosis patients. Poster presented at the 18th International Myeloma Workshop; September 18, 2021. Vienna, Austria. [abstract] Clin Lymphoma Myeloma Leuk. 2021 Oct; 21(Suppl 2):S106. doi: 10.1016/S2152-2650(21)02257-6

Richardson D, Zhan L, Mahtani R, McRoy L, Mitra D, Reynolds M, Odom D, Hollis K, Kaye JA, Jones C, Hargis J. A prospective observational study of patient-reported functioning and quality of life in advanced and metastatic breast cancer utilizing a novel mobile application. Breast Cancer Res Treat. 2021 May;187(1):113-24. doi: 10.1007/s10549-020-06082-7

Stenehjem DD, Telford C, Unni SK, Bauer H, Sainski A, Deka R, Schauerhamer MB, Ye X, Tak CR, Ma J, Dalvi TB, Gutierrez L, Kaye JA, Tyczynski JE, Brixner DI, Biskupiak JE. BRCA testing and outcomes in women with breast cancer. Breast Cancer Res Treat. 2021 Apr;186(3):839-50. doi: 10.1007/s10549-020-06038-x

Hackshaw MD, Danysh HE, Singh J, Ritchey ME, Ladner A, Taitt C, Camidge DR, Powell CA. Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2020 Jun 26;183(1):23-39. doi: 10.1007/s10549-020-05754-8

Liede A, Mansfield CA, Metcalfe KA, Price MA, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Snyder C, Lynch HT, Friedman S, Amelio J, Posner J, Narod SA, Lindeman GJ, Evans DG. Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment. Breast Cancer Res Treat. 2017 Sep;165(2):433-44. doi: 10.1007/s10549-017-4332-3.

Dine JL, O'Sullivan CC, Voeller D, Greer YE, Chavez KJ, Conway CM, Sinclair S, Stone B, Amiri-Kordestani L, Merchant AS, Hewitt SM, Steinberg SM, Swain SM, Lipkowitz S. The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. Breast Cancer Res Treat. 2016 Jan;155(2):235-51. doi: 10.1007/s10549-015-3673-z.

Police RL, Trask PC, Wang J, Olivares R, Khan SB, Abbe A, Colosia AD, Njue AI, Sherrill EH, Ruiz-Soto R, Kaye JA, Hamadani M. Randomized controlled trials in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):199-207. doi: 10.1016/j.clml.2014.09.008

Njue A, Colosia A, Trask PC, Olivares R, Khan S, Police R, Abbe A, Wang J, Kaye JA, Ruiz-Soto R, Awan F. Clinical efficacy and safety in relapsed/refractory mantle cell lymphoma: a systematic literature review. Clin Lymphoma Myeloma Leuk. 2015 Jan;15(1):1-12. doi: 10.1016/j.clml.2014.03.006

Colosia A, Njue A, Trask PC, Olivares R, Khan S, Abbe A, Police R, Wang J, Ruiz-Soto R, Kaye JA, Awan F. Clinical efficacy and safety in relapsed/refractory diffuse large B-cell lymphoma: a systematic literature review. Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):343-55. doi: 10.1016/j.clml.2014.02.012

Maclean EN, Stone IS, Ceelen F, Garcia-Albeniz X, Sommer WH, Petersen SE. Reporting standards in cardiac MRI, CT, and SPECT diagnostic accuracy studies: analysis of the impact of STARD criteria. Eur Heart J Cardiovasc Imaging. 2014 Jun;15(6):691-700. doi: 10.1093/ehjci/jet277

Blum JL, Kohles J, McKenna E, Scotto N, Hu S, Odom D, Kaye JA, Glück S. Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials. Breast Cancer Res Treat. 2011 Jan 1;125(2):431-9.

Zhou X, Cella D, Cameron D, Amonkar MM, Segreti A, Stein S, Walker M, Geyer CE. Lapatinib plus capecitabine versus capecitabine alone for HER2+(ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Res Treat. 2009 Oct 1;117(3):577-89. doi: 10.1007/s10549-009-0310-8

Candrilli S, Bell T, Irish W, Morris E, Goldman S, Cairo MS. A comparison of inpatient length of stay and costs among patients with hematologic malignancies (excluding Hodgkin disease) associated with and without acute renal failure. Clin Lymphoma Myeloma Leuk. 2008 Feb 29;8(1):44-51.

Yost KJ, Yount SE, Eton DT, Silberman C, Broughton-Heyes A, Cella D. Validation of the Functional assessment of cancer therapy-Breast Symptom Index (FBSI). Breast Cancer Res Treat. 2005 Apr 1;90(3):295-8.